UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2019

Commission file number: 001-38556

ENTERA BIO LTD.

(Exact Name of Registrant as Specified in Its Charter)

Kiryat Hadassah
Minrav Building – Fifth Floor
Jerusalem, Israel
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

CONTENTS

This report on Form 6-K of the registrant consists of a press release issued by the registrant on August 20, 2019, attached hereto as an exhibit and incorporated by reference herein.

Exhibit

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ENTERA BIO LTD.
(Registrant)

By: /s/Adam Gridley
Name: Adam Gridley
Title: Chief Executive Officer

Date: August 20, 2019

Exhibit 99.1

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

AS OF JUNE 30, 2019

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

AS OF JUNE 30, 2019

TABLE OF CONTENTS

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(UNAUDITED)

	June 30 2019	December 31 2018
	U.S. dollars in thousands	
A s s e t s		
CURRENT ASSETS:		
Cash and cash equivalents	7,386	7,506
Short-term bank deposits	-	4,015
Accounts receivable	-	725
Other current assets	486	220
TOTAL CURRENT ASSETS	7,872	12,466
NON-CURRENT ASSETS:		
Property and equipment	231	224
Right to use assets	327	-
Intangible assets	621	651
TOTAL NON-CURRENT ASSETS	1,179	875
TOTAL ASSETS	9,051	13,341
Liabilities and shareholders' equity		
CURRENT LIABILITIES:		
Accounts payable:		
Trade	494	473
Other	939	1,090
Lease liabilities	163	-
Contract liabilities	151	225
TOTAL CURRENT LIABILITIES	1,747	1,788
NON-CURRENT LIABILITIES:		
Warrants to purchase ordinary shares	578	1,372
Lease liabilities	190	-
Severance pay obligations, net	68	65
TOTAL NON-CURRENT LIABILITIES	836	1,437
TOTAL LIABILITIES	2,583	3,225
COMMITMENTS AND CONTINGENCIES		
SHAREHOLDERS' EQUITY:		
Ordinary Shares, NIS 0.0000769 par value:		
Authorized - as of June 30, 2019 and December 31, 2018, 140,010,000 shares; issued and outstanding: as of June 30, 2019, and December 31, 2018 – 11,899,159 shares and 11,459,780 shares, respectively.	*	*
Accumulated other comprehensive income	41	41
Other reserves	13,563	13,019
Additional paid in capital	49,342	49,173
Accumulated deficit	(56,478)	(52,117)
TOTAL SHAREHOLDERS' EQUITY	6,468	10,116
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	9,051	13,341

* Represents an amount less than one thousand US dollars.

The accompanying notes are an integral part of the condensed consolidated financial statements.

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (INCOME)

(UNAUDITED)

	Six months ended June 30		Three months ended June 30	
	2019	2018	2019	2018
	U.S. dollars in thousands			
REVENUE	(74)	-	(74)	-
COST OF REVENUE	62	-	62	-
RESEARCH AND DEVELOPMENT EXPENSES, NET	3,448	4,658	1,413	1,765
GENERAL AND ADMINISTRATIVE EXPENSES (INCOME)	1,684	854	628	(409)
OPERATING LOSS	5,120	5,512	2,029	1,356
FINANCIAL EXPENSES (INCOME):				
Income from change in fair value of financial liabilities at fair value	(794)	(2,896)	(682)	(2,876)
Other financial expenses (income), net	35	(23)	19	(43)
FINANCIAL INCOME, net	(759)	(2,919)	(663)	(2,919)
NET COMPREHENSIVE LOSS (INCOME) FOR THE PERIOD	4,361	2,593	1,366	(1,563)
	U.S. dollars		U.S. dollars	
LOSS (INCOME) PER ORDINARY SHARE:				
Basic	0.38	0.58	0.12	(0.35)
Diluted	0.38	0.70	0.12	0.11
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:				
Basic	11,601,289	4,490,720	11,742,797	4,490,720
Diluted	11,601,289	4,735,510	11,742,797	9,640,930

The accompanying notes are an integral part of the condensed consolidated financial statements.

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)

(UNAUDITED)

	Number of Ordinary Shares	Ordinary Shares-Amount	Accumulated other comprehensive income	Other reserve	Additional paid in capital	Accumulated deficit	Total
		U.S dollars in thousands					
BALANCE AT JANUARY 1, 2018	4,490,720	*	41	7,361	2,853	(41,813)	(31,558)
CHANGES FOR SIX MONTHS ENDED JUNE 30, 2018:							
Net loss for the period						(2,593)	(2,593)
Share-based compensation	-	-	-	597	-	-	597
Reclassification of capital contribution from controlling shareholder	-	-	-	(51)	51	-	-
Reclassification due to share-based compensation forfeited	-	-	-	(11)	11	-	-
BALANCE AT JUNE 30, 2018	4,490,720	*	41	7,896	2,915	(44,406)	(33,554)
BALANCE AT JANUARY 1, 2019	11,459,780	*	41	13,019	49,173	(52,117)	10,116
CHANGES FOR SIX MONTHS ENDED JUNE 30, 2019:							
Net loss for the period	-	-	-	-	-	(4,361)	(4,361)
Exercise of options to ordinary shares	439,379	*	-	(143)	169	-	26
Share-based compensation				687			687
BALANCE AT JUNE 30, 2019	11,899,159	*	41	13,563	49,342	(56,478)	6,468

* Represents an amount less than one thousand US dollars.

The accompanying notes are an integral part of the condensed consolidated financial statements.

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)

(UNAUDITED)

	Number of Ordinary Shares	Ordinary Shares-Amount	Accumulated other comprehensive income	Other reserve	Additional paid in capital	Accumulated deficit	Total
		U.S dollars in thousands					
BALANCE AT MARCH 31, 2018	4,490,720	*	41	8,520	2,915	(45,969)	(34,493)
CHANGES FOR THREE MONTHS ENDED JUNE 30, 2018:							
Net Income (loss) for the period	-	-	-	-	-	1,563	1,563
Share-based compensation	-	-	-	(624)	-	-	(624)
BALANCE AT JUNE 30, 2018	4,490,720	*	41	7,896	2,915	(44,406)	(33,554)
BALANCE AT MARCH 31, 2019	11,459,780	*	41	13,560	49,173	(55,112)	7,662
CHANGES FOR THREE MONTHS ENDED JUNE 30, 2019:							
Net loss for the period	-	-	-	-	-	(1,366)	(1,366)
Exercise of options to ordinary shares	439,379	*	-	(143)	169	-	26
Share-based compensation	-	-	-	146	-	-	146
BALANCE AT JUNE 30, 2019	11,899,159	*	41	13,563	49,342	(56,478)	6,468

* Represents an amount less than one thousand US dollars.

The accompanying notes are an integral part of the condensed consolidated financial statements.

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

(UNAUDITED)

	Six months ended June 30	
	2019	2018
	(Unaudited)	
	U.S dollars in thousands	
CASH FLOWS USED IN OPERATING ACTIVITIES:		
Net loss for the period	(4,361)	(2,593)
Adjustments required to reflect net cash used in operating activities (see appendix A)	304	(2,614)
Net cash used in operating activities	(4,057)	(5,207)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:		
Short-term bank deposits	4,000	-
Purchase of property and equipment	(37)	(68)
Net cash provided by (used in) investing activities	3,963	(68)
CASH FLOWS USED IN FINANCING ACTIVITIES:		
Principle element of lease payments	(52)	-
Proceeds from exercise of options	26	-
Net cash used in financing activities	(26)	-
NET DECREASE IN CASH AND CASH EQUIVALENTS	(120)	(5,275)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	7,506	11,746
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	7,386	6,471

The accompanying notes are an integral part of the condensed consolidated financial statements.

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

(UNAUDITED)

	Six months ended June 30	
	2019	2018
	(Unaudited)	
	U.S dollars in thousands	
APPENDIX A:		
Adjustments required to reflect net cash used in operating activities:		
Depreciation and amortization	122	27
Change in fair value of financial liabilities at fair value	(794)	(2,896)
Financial expenses	58	32
Changes in severance pay obligations, net	3	(4)
Share-based compensation	687	597
	76	(2,244)
Changes in working capital:		
Decrease in accounts receivables	725	-
Increase in other current assets	(266)	(346)
Decrease in contract liability	(74)	-
Increase (decrease) in accounts payable and accruals:		
Trade	21	(334)
Other	(151)	342
	255	(338)
Cash used for operating activities -		
Interest paid	(27)	(32)
	304	(2,614)

The accompanying notes are an integral part of the condensed consolidated financial statements.

NOTE 1 - GENERAL INFORMATION:

a. General:

1) Entera Bio Ltd. (collectively with its subsidiary, the "Company") was incorporated on September 30, 2009 and commenced operation on June 1, 2010. On January 8, 2018, the Company incorporated Entera Bio Inc., a fully owned subsidiary based in Delaware USA. The Company is a clinical-stage biopharmaceutical company, focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. Currently the Company is focused on the development of oral capsules for the treatment of osteoporosis and hypoparathyroidism. Our lead oral PTH product candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism.

2) Initial Public Offering (IPO)–
The Company filed final prospectus with the Securities and Exchange Commission ("SEC") which became effective on June 27, 2018. On July 2, 2018 the Company Completed the IPO in the Nasdaq Capital Market (the “Nasdaq”).

3) Since the Company is engaged in research and development activities, it has not derived significant income from its activities and has incurred accumulated losses in the amount of $56,478 thousand through June 30, 2019 and cash outflows from operating activities. The Company's management is of the opinion that its available funds as of June 30, 2019 will not allow the Company to execute its development plans in the next twelve months. These factors raise substantial doubt as to the Company's ability to continue as a going concern.

   Management is in the process of evaluating various financing alternatives in the public or private equity markets, debt financings, government grants or through license of the company's technology to additional external parties through partnerships or research collaborations as the Company will need to finance future research and development activities, general and administrative expenses and working capital through fund raising. However, there is no certainty about the Company's ability to obtain such funding.

   The financial information has been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. If the Company does not raise the requisite funds, it will need to curtail or cease operations. These financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

4) On December 10, 2018, the Company entered into a research collaboration and license agreement (the “Amgen Agreement”) with Amgen Inc. (“Amgen”) in inflammatory disease and other serious illnesses. Pursuant to the Amgen Agreement, the Company and Amgen will use the Company’s proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has options to select up to two additional programs to include in the collaboration. Amgen is responsible for the clinical development, regulatory approval, manufacturing and worldwide commercialization of the programs.

NOTE 1 - GENERAL INFORMATION (Cont.)**:**

The Company granted Amgen an exclusive, worldwide, sublicensable license under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and commercialize the applicable products. The Company will retain all intellectual property rights to its drug delivery technology, and Amgen will retain all rights to its large molecules and any subsequent improvements, and ownership of certain intellectual property developed through the performance of the collaboration is to be determined by U.S. patent law.

Pursuant to the terms of the Amgen Agreement, Amgen is required to make aggregate payments of up to $270 million upon achievement of various clinical and commercial milestones or its exercise of options to select additional two programs to include in the collaboration, as well as tiered royalty payments ranging from the low to mid-single digits based on the level of Amgen's net sales of the applicable products. Amgen is required to pay for the initial program $450,000 for the second year of preclinical services to be provided by the Company and must reimburse the Company for further expenses as shall be agreed between the parties. In January 2019, as required by the Amgen Agreement, Amgen paid the Company a non-refundable and non-creditable initial technology access fee of $725,000.

As of December 31, 2018, the company recognized $500,000 in revenue. The company will recognize the remaining $225,000 received from Amgen according to the input method. During the six months ended June 30, 2019, the company recorded revenues in the amount of $74 thousand.

Amgen's obligation to pay royalties with respect to a product in a particular country commences upon the first commercial sale of such product in such country and expires on a country-by-country and product-by-product basis on the later of (a) the date on which the sale of the product is no longer covered by a valid claim of a patent licensed to Amgen under the Amgen Agreement, and (b) the tenth anniversary of the first commercial sale of such product in such country.

The term of the Amgen Agreement commenced on December 10, 2018, and unless earlier terminated, shall continue in full force and effect, on a product-by-product basis, until expiration of the last-to-expire royalty term with respect to such product.

b. Approval of financial statements

These financial statements were approved by the Company's Board of Directors on August 15, 2019.

NOTE 2 - BASIS OF PREPARATION

The Company's condensed consolidated interim financial statements as of June 30, 2019 and for the six months then ended (the "interim financial statements") have been prepared in accordance with International Accounting Standard No. 34, "Interim Financial Reporting" ("IAS 34"). These interim financial statements, which are unaudited, do not include all disclosures necessary for a complete presentation of financial position, comprehensive loss, changes in shareholders' equity and cash flows in conformity with generally accepted accounting principles. The condensed consolidated interim financial statements should be read in conjunction with the Company's annual financial statements as of December 31, 2018 and for the year then ended and their accompanying notes, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the IASB.

The results of operations for the six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period.

The accounting policies and calculation methods applied in the preparation of the interim financial statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2018 and for the year then ended.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

Newly issued and recently adopted Accounting Pronouncements

IFRS 16, "Leases"

a. Adjustments recognized on adoption of IFRS 16

The Company has adopted IFRS 16 retrospectively from January 1, 2019 but has not restated comparatives for the 2018 reporting period, as permitted under the specific transitional provisions in the standard. On adoption of IFRS 16, the Company recognized lease liabilities in relation to leases which had previously been classified as "operating leases" under the principles of IAS 17, "Leases". These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate as of January 1, 2019, which was 16%. The remeasurements to the lease liabilities were recognized as adjustments to the related right-of-use assets immediately after the date of initial application. The associated right-of-use assets for facility leases were measured on a retrospective adjusted basis.

Following is the composition of right-of-use assets by type:

	January 1, 2019	June 30, 2019
Facility	151	314
Vehicles	15	13
Total right-of-use asset	166	327

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES (Cont.)**:**

The following table summarize the contractual obligations:

	Payments due by period		
	Total	Less than 1 year	1 - 3 years
	(in thousands)		
Operating leases for facility and vehicles as of December 31, 2018	$ 123	$ 87	$ 36
Operating leases for facility and vehicles as of June 30, 2019	$ 424	$ 175	$ 249

b. Practical expedients applied on adoption of IFRS 16

In applying IFRS 16 for the first time, the Company had used the following practical expedients permitted by the standard:

- Use of a single discount rate to a portfolio of leases with reasonably similar characteristics;
- Reliance on previous assessments on whether leases are onerous;
- Exclusion of initial direct costs for the measurement of the right-of-use asset at the date of initial application;
- Use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease.

The Company has also elected not to reassess whether a contract is, or contains, a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Company relied on its assessment made applying IAS 17 and IFRIC 4, “Determining whether an Arrangement contains a Lease.”

c. Other information relating to IFRS 16

In January 2019, the Company entered into a new lease agreement for the building it uses in consideration of approximately additional $98 thousand per year. The new lease started in February 2019. The annual lease consideration is in total amount of $164 thousand.

As part of the new agreement, the whole lease agreement will expire on June 30, 2023 with a one-time option for the Company to early terminate the agreement on December 31, 2021 subject to a notice period of six months.

As of June 30, 2019, the Company provided bank guarantees of approximately $30 thousand, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES (Cont.)**:**

	Six months ended	Three months ended
	June 30, 2019	
Depreciation expense:		
Facility	55	29
Vehicles	6	4
Financial expense	27	15
Cash paid for amounts included in the measurement of lease liabilities	79	44
Right of use assets obtained in exchange for new operating lease liabilities	223	-

NOTE 4 – FINANCIAL RISK FACTORS

The Company's activities expose it to a variety of financial risks.

The condensed interim financial statements do not include all financial risk information and disclosures required in the annual financial statements; they should be read in conjunction with the Company's annual financial statements as of December 31, 2018.

There have been no changes in the risk management policies since the year end.

NOTE 5 – FAIR VALUE MEASUREMENT

The Company measures fair value and discloses fair value measurements for financial assets. Fair value is based on the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of warrants to purchase ordinary shares is based on level 1 measurement as of June 30, 2019. As of June 30, 2018, the fair value of the Company's financial liabilities measured at fair value was based on level 3 measurement.

NOTE 6 – SHARE BASED COMPENSATION

1) Options grants

a) On January 17, 2019, the Company granted options to purchase 124,000 ordinary shares to certain employees, with an exercise price of $3.97. The options vest over 4 years from the date of grant; 25%will vest on the first anniversary of the date of grant and the remaining 75% options shall vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of the options at the date of grant was $341 thousand.

b) On January 17, 2019, the Company's Board of Directors approved to grant options to purchase 25,000 ordinary shares to the CMO, with an exercise price of $3.97. From the total options, 25% will vest on March 1, 2019 and the remaining 75% options shall vest in twelve equal quarterly installments over the next three years starting January 17,2019. The fair value of the options at the date of grant was $68 thousand.

c) On January 17, 2019, the Company's Board of Directors approved to grant options to purchase 201,828 ordinary shares to non-executive directors of the Company, with an exercise price of $3.97. The options will vest over 3 years in twelve equal quarterly instalments starting in the vesting commencement date (as described in each agreement). The fair value of the options at the date of grant was $531 thousand.

2) Exercise of options

During the six months ended June 30, 2019, an Executive officer and a former Executive officer exercised 439,379 options into 439,379 ordinary shares for a total consideration of $26 thousand dollars.

NOTE 7 – BASIC AND DILUTED LOSS PER SHARE

Basic

Basic loss (income) per share is calculated by dividing the result attributable to equity holders of the Company by the weighted average number of Ordinary Shares in issue during the period.

Diluted

All outstanding options and warrants have been excluded from the calculation of the diluted loss per share for the six and three months ended June 30, 2019 since their effect was anti-dilutive. The total number of ordinary shares which were excluded from the calculation of diluted loss per share was 5,529,645 and 5,450,825 for the six and three months ended June 30, 2019, respectively.

All outstanding options, the 2012 Convertible Loan, preferred shares, warrants to issue preferred shares B and warrants to issue preferred shares A have been excluded from the calculation of the diluted loss per share for the six months ended June 30, 2018 since their effect was anti-dilutive. The total number of shares related to the outstanding options, the 2012 Convertible Loan, preferred shares, warrants to issue preferred shares B and warrants to issue preferred shares A excluded from the calculation of diluted loss per share was 9,862,970 for the six months ended June 30, 2018.

All outstanding options, the 2012 Convertible Loan, warrants to Preferred Shares B and warrants to issue preferred shares A have been excluded from the calculation of the diluted income per share for the three months ended June 30, 2018 since their effect was anti-dilutive. The total number of shares related to the outstanding options, the 2012 Convertible Loan, warrants to Preferred Shares B and warrants to issue preferred shares A excluded from the calculation of diluted income per share was 4,961,320 for the three months ended June 30, 2018.

NOTE 7 – BASIC AND DILUTED LOSS PER SHARE (Cont.)**:**

	Six months ended June 30		Three months ended June 30	
	2019	**2018**	**2019**	**2018**
	U.S. dollars (except for share numbers)			
Loss (Income) attributable to equity holders of the Company	4,361,000	2,593,000	1,366,000	(1,563,000)
Less:				
Income from change in fair value of financial liabilities at fair value	-	(727,000)	-	(2,599,000)
Loss used for the computation of diluted loss per share	4,361,000	3,320,000	1,366,000	1,036,000
Weighted average number of Ordinary Shares used in the computation of basic loss (income) per share	11,601,289	4,490,720	11,742,797	4,490,720
Add:				
Weighted average number of additional shares issuable upon the assumed conversion/ exercise of:				
Preferred shares	-	-	-	4,905,420
Warrants to issue preferred shares and shares	-	244,790	-	244,790
	-	244,790	-	5,150,210
Weighted average number of shares used in the computation of diluted loss per share	11,601,289	4,735,510	11,742,797	9,640,930
Basic loss (income) per Share	0.38	0.58	0.12	(0.35)
Diluted loss per Share	0.38	0.70	0.12	0.11

NOTE 8 - SUBSEQUENT EVENTS

A. In July 2019, one of the Company' shareholders exercised his right to acquire 32,250 ordinary shares for a purchase price of $3.69 per share (upon achievement of the second milestone) in accordance with its preferred share A purchase agreement signed in 2014 and its following amendments. The total consideration was $120 thousand and was set off in amount of $20 thousand as per it's consulting agreement with the company signed in 2014.

B. During July 2019, a former Executive officer exercised 25,111 options into 25,111 ordinary shares for a total consideration of $60 thousand dollars.

C. On August 5, 2019, the Company appointed Mr. Adam Gridley as the Company's Chief Executive Officer, effective August 5, 2019. In connection with Mr. Gridley appointment as the Company's new Chief Executive Officer, the Company's Board of Directors granted Mr. Gridley options to purchase 696,587 ordinary shares at an exercise price of $2.75 per share. The options vest over 4 years from the date of grant; 1/4 vest on the date of grant and the remaining vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair value of the options at the date of grant was $1,223 thousand. The grant is subject to the Company's shareholders' approval.

Exhibit 99.2

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes to the financial statements, which are included in this Report of Foreign Private Issuer on form 6-K. You should also read the following discussion in conjunction with the information contained in our annual report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission on March 28, 2019 We have prepared our financial statements in accordance with IFRS as issued by IASB.

This Report of Foreign Private Issuer on Form 6-K of Entera Bio Ltd. includes forward looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include all statements that are not historical facts and can be identified by words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," and similar expressions or phrases. We have based these forward-looking statements largely on our management's current expectations and future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

Forward-looking statements include, but are not limited to, statements about:

- our operation as a development stage company with limited operating history and a history of operating losses and our ability to fund our operations going forward;
- our ability to develop and advance product candidates into, and successfully complete, clinical studies;
- uncertainty surrounding whether any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized, including that we will be able to demonstrate to regulators the noninferiority of EB613 in comparison to Forteo as part of a 505(b)(2) submission or that we will be able to demonstrate to regulation the clinical superiority of EB612 over Natpara, which is required to overcome Natpara's drug exclusivity;
- our competitive position, especially with respect to Natpara, our key competitor for hypoparathyroidism treatment;
- our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern absent access to sources of liquidity;
- our ability to use and expand our drug delivery technology to other product candidates;
- the pricing and reimbursement of our product candidates, if approved;
- our being subject to ongoing regulatory obligations if our products secure regulatory approval;
- our ability to develop sales, marketing and distribution infrastructure;
- our reliance on third parties to conduct our clinical trials and on third-party suppliers to supply or produce our product candidates;
- our ability to achieve market acceptance for our product candidates;
- our ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights;
- our ability to retain key personnel and recruit additional qualified personnel;

- our expectations about cash use;
- our ability to manage growth; and
- other risk factors discussed under “Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2018.

All forward-looking statements in this Report of Foreign Private Issuer on Form 6-K involve risks, assumptions and uncertainties and made as of the date of this Report of Foreign Private Issuer on Form 6-K. You should not rely upon forward-looking statements as predictors of future events. The occurrence of the events described, and the achievement of expected results, depend on many events, some or all of which are not predictable or within our control. Actual results may differ materially from expected results. See the sections below “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 20-F for the year ended December 31, 2018 for a more complete discussion of these risks, assumptions and uncertainties and for other risks and uncertainties. These risks, assumptions and uncertainties are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results. All of the forward-looking statements we have included in this Report of Foreign Private Issuer on Form 6-K are based on information available to us on the date of this Report of Foreign Private Issuer on Form 6-K. We undertake no obligation, and specifically decline any obligation, to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this Report of Foreign Private Issuer on Form 6-K or in our Prospectus might not occur.

All references to “we,” “us,” “our,” “Entera”, “the Company” and “our Company” in this Report of Foreign Private Issuer on Form 6-K are to Entera Bio Ltd. and its U.S. subsidiary Entera Bio Inc., unless the context otherwise requires.

Overview

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. We are initially applying our technology to develop an oral formulation of parathyroid hormone, or PTH, which has been approved in the United States in injectable form for over a decade. Following FDA guidance received in the fourth quarter of 2018, indicating that a fracture study would not be required for a 505b2 in osteoporosis, we decided to accelerate our development of EB613 for osteoporosis. As planned, a phase 2, dose ranging study was initiated by the end of Q2 2019. This double blinded, placebo controlled, study will evaluate three different doses in postmenopausal women with low bone mass. The study is being developed to include up to 160 patients dosed once daily for a period of 6 months. Human PTH (1-34) is a known anabolic treatment currently available as a daily subcutaneous injection, Forteo ® (marketed by Eli Lilly ®) with a known effect on bone formation biomarkers and bone mineral density (BMD). The primary endpoint of this study will be bone formation biomarkers at 3 months with an additional evaluation at 6 months, along with a BMD readout. The study was approved by the Israeli Ministry of Health and is planned to be conducted at the osteoporosis clinics of 4 leading medical centers in Israel. These clinics have participated in a number of multinational osteoporosis trials for large pharmaceutical companies. All lab tests will be processed by an accredited central lab and BMD measurements will be monitored and analyzed in the US by a leading US contract research organization (CRO).

The 3-month biomarker results are expected to provide preliminary insight into the efficacy of the oral PTH treatments and preliminary results may be obtained once the first half of the study population has been dosed for this period. A full study report will be generated upon completion of the 6 month biomarker and BMD analysis. It should be noted that preparations for the EB613 Phase 3 study are likely to commence after reviewing the 3-month biomarker data. The Company has already created a Phase 3 study outline and currently envisages a trial with a partner comparing EB613 to Forteo, enrolling 600 to 800 patients and with a primary endpoint based on non-inferiority in BMD outcome. Other details, including the EB613 dose and the length of the study, are expected to be finalized based on the results obtained from the Phase 2 study.

We are also developing an additional oral PTH product candidate, EB612, which has successfully completed a Phase 2a trial for hypoparathyroidism, a rare condition in which the body fails to produce sufficient amounts of PTH. We completed a clinical trial to evaluate the PK/PD profile of various EB612 dose regimens and Natpara. Data processing and statistical analysis is currently ongoing and results will be presented at a scientific meeting later this year. Following the evaluation of our PK/PD clinical trial and subject to receipt of additional funding, we expect in the future to initiate a Phase 2b/3 clinical trial of EB612 in hypoparathyroidism which would potentially support a submission for regulatory approval of EB612. The FDA and the EMA have granted EB612 orphan drug designation for the treatment of hypoparathyroidism.

In addition, we intend to use our technology as a platform for the oral delivery of other protein and large molecule therapeutics as well as novel therapeutics. We have signed a license agreement with Amgen and may sign additional licensing or collaboration agreements in the future. We intend to utilize future funds, as available, to advance EB613 and EB612 for advanced clinical studies and ultimately for regulatory approval.

Financial Results

Comparison of Six-Month Period Ended June 30, 2019 and 2018

	(unaudited) Six Months Ended June 30,		Increase (Decrease)	
	2019	**2018**	**$**	**%**
	(In thousands, except for percentage information)			
Revenues	$ (74)	$ -	$ 74	100%
Cost of revenues	62	-	62	100%
Operating Expenses:				
Research and development, net	3,448	4,658	(1,210)	(26)%
General and administrative	1,684	854	830	97%
Operating loss	5,120	5,512	(392)	(7)%
Financial income, net	(759)	(2,919)	2,160	(74)%
Net loss	$ 4,361	$ 2,593	$ 1,768	68%

Revenues. Revenues for the six months ended June 30, 2019 are comprised of revenue from services provided to Amgen under the license agreement.

Research and development, net expenses. Research and development expenses for the six months ended June 30, 2019 were $3.5 million, compared to $4.7 million for the six months ended June 30, 2018, a decrease of $1.2 million, or 26%. The decrease in research and development expenses was primarily attributed to a decrease of $0.8 million in materials, clinical manufacturing and production capabilities and a decrease of $0.5 million in share-based compensation expenses due to higher fair value of the options granted to the previous CMO in the same period last year. The decrease was partially offset by an increase of $0.1 million in salaries and related expenses mainly due to hiring full time employees in the US during the first quarter of 2018.

General and administrative expenses. General and administrative expenses for the six months ended June 30, 2019 were $1.7 million, compared to $0.9 million for the six months ended June 30, 2018, an increase of $0.8 million, or 97%. The increase in general and administrative expenses was primarily attributed to an increase of $0.6 million in share-based compensation expenses due to a reversal of share based compensation recorded in the previous period as the result of termination of services of our previous Chairman of the board, in the same period in the prior year, increase of $0.1 million for insurance expenses and $0.1 million for investor relation expenses due to regulation and the requirements of a public company.

Financial income, net. Financial income, net for the six months ended June 30, 2019 was $0.8 million, compared to financial income, net of $2.9 million for the six months ended June 30, 2018, a decrease of $2.2 million. Financial income, net for the six months ended June 30, 2019 resulted mainly from the change in the fair value of warrants to purchase ordinary shares that were recorded as a financial liability at fair value through profit or loss.During the same period last year, the company recognized financial income from changes in fair value of financial liabilities comprised of convertible loans, preferred shares and warrants which were converted or recorded as equity upon completion of our initial public offering (IPO). During the six months ended June 30, 2019 and 2018, we recorded a gain of $0.8 million and $2.9 million, respectively, on changes in fair value of financial liabilities.

Comprehensive loss. Comprehensive loss for the six months ended June 30, 2019 was approximately $4.4 million, compared with approximately $2.6 million in the same period in 2017 an increase of approximately $1.8 million, or 68%.

Basic and diluted Loss (income) per share. Basic and dilutive loss per share for the six months ended June 30, 2019 was $0.38, compared with $0.58 and $0.7, respectively, for the six months ended June 30, 2018.

Comparison of Three-Month Period Ended June 30, 2019 and 2018

	(unaudited) Three Months Ended June 30,		Increase (Decrease)	
	2019	**2018**	**$**	**%**
	(In thousands, except for percentage information)			
Revenues	$ (74)	$ -	$ 74	100%
Cost of revenue	62	-	62	100%
Expenses:				
Research and development, net \	1,413	1,765	(352)	(20)%
General and administrative	628	(409)	1,037	254%
Operating loss	2,029	1,356	673	50%
Financial income, net	(663)	(2,919)	(2,256)	(77)%
Net loss (Income)	$ 1,366	$ (1,563)	$ 2,929	187

Revenues. Revenues for the three months ended June 30, 2019 are comprised of revenue from services provided to Amgen under the license agreement.

Research and development, net expenses. Research and development expenses for the three months ended June 30, 2019 were $1.4 million, compared to $1.8 million for the three months ended June 30, 2018, a decrease of $0.4 million, or 20%. The decrease in research and development expenses was primarily attributed to a decrease of approximately $0.3 million in materials, clinical manufacturing and production capabilities and $0.2 million in clinical trials, which was partially offset by an increase of $0.1 million in other research and development expenses primarily for consulting with regard to regulation expenses.

General and administrative expenses (income). General and administrative expenses for the three months ended June 30, 2019 were $0.6 million, compared to a general and administrative income of $0.4 million for the three months ended June 30, 2018, an increase in expenses of $1.0 million. The increase in general and administrative expenses was primarily attributed to an increase of $0.9 million in share-based compensation due to a reversal of compensation recorded in the previous period as a result of termination of services of our previous Chairman of the board. In addition, insurance expenses increased by $0.1 million.

Financial income, net. Financial income, net for the three months ended June 30, 2019 was $0.7 million, compared to a financial income, net of $2.9 million for the three months ended June 30, 2018. Financial income, net for the three months ended June 30, 2019 resulted mainly from the change in the fair value of warrants to purchase shares that were recorded as a financial liability at fair value through profit or loss. During the three months ended June 30, 2019 and 2018, we recorded a gain of $0.7 million and $2.9 million, respectively, on changes in fair value of financial liabilities.

Comprehensive loss (income), net. Comprehensive loss for the three months ended June 30, 2019, was approximately $1.4 million, compared with a comprehensive income of approximately $1.6 million in the same period in 2018 an increase in expenses of approximately $2.9 million.

Basic and diluted Loss (income) per share.
Basic and diluted loss per share for the three months ended June 30, 2019 was $0.12 compared with a basic income of $0.35 and diluted loss per share of $0.11, for the three months ended June 30, 2018.

Liquidity and Capital Resources

Since our inception through June 30, 2019, we have raised a total of $31.3 million through private offerings, convertible loans and grants from governmental authorities.

As of June 30, 2019, we had cash and cash equivalents of approximately $7.4 million. As of December 31, 2018, we had cash and cash equivalents of approximately $11.5 million (including $4 million in short-term bank deposits).

Net Cash Used in Operating Activities

Net cash used in operating activities for the six months ended June 30, 2019 was $4.1 million, consisting primarily of our operating loss of $5.1 million arising mainly from research and development expenses and general and administrative expenses, partially offset by $0.7 million in share-based compensation and a $0.3 million decrease in working capital.

Net cash used in operating activities for the six months ended June 30, 2018 was $5.2 million, consisting primarily of our operating loss of $5.5 million arising mainly from research and development expenses and general and administrative expenses and a $0.3 million increase in working capital, which was partially offset by $0.6 million of share-based compensation.

The decrease in cash used in operating activities for the six months ended June 30, 2019 compared to the same period of 2018, was mainly due to a decrease of $0.8 million for materials, clinical manufacturing and production capabilities, payment received from Amgen of $0.7 million which was offset by other working capital due to an increase in professional services and other expenses related to regulation and the requirements of a public company.

Net Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities for the six months ended June 30, 2019 were $4.0 million primarily attributed to the release of a short-term bank deposit.

Net cash used in investing activities for the six months ended June 30, 2018 consisted of purchase of property, plant and equipment.

Net Cash Used in Financing Activities

Net cash used in financing activities for the six months ended June 30, 2019 was primarily due to lease payments which were partially offset by cash received from exercise of options granted to employees.

No cash provided by or used in financing activities for the six months ended June 30, 2018.

Exhibit 99.3

Entera Bio Ltd.

Adam Gridley, CEO
Tel: +972-2-532-7151
adam@enterabio.com

INTERNATIONAL INVESTOR RELATIONS

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

Entera Bio Reports Second Quarter 2019 Financial Results and Provides Operating Update

- Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020
- Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results expected to be presented in Q3 2019.
- Appointed Adam Gridley as Chief Executive Officer
- Conference call and live webcast today at 8:30 am Eastern Time

JERUSALEM, Israel & BOSTON, Mass. (August 20, 2019) – Entera Bio Ltd. (NASDAQ: ENTX) today provided a corporate update and reported financial results for second quarter ended June 30, 2019.

“Entera’s evolution into one of the leading oral delivery companies for human parathyroid hormone (“PTH”) and other biologics or large molecule drugs continues at a rapid pace. For our internal proprietary Phase 2 therapeutic pipeline, we continue to execute on our two lead PTH programs with a number of near-term milestones over the coming year,” stated Adam Gridley, CEO of Entera. “We are pleased to advance our lead program in osteoporosis with the recent initiation of a Phase 2 dose ranging study for EB613, our oral PTH candidate. Given the potential commercial potential for an orally delivered drug for osteoporosis, and the recent FDA guidance on endpoints via the 505(b)2 regulatory pathway, we’ve accelerated our clinical efforts for this program. This study is designed to build upon the strong safety and efficacy data generated to date, and inform the appropriate dose to evaluate for our global registrational Phase 3 study to support potential FDA review. We have also completed Part 2 of our Phase 2 PK/PD study of Oral PTH in hypoparathyroidism, and we plan to present them at a scientific meeting in the third quarter of 2019.”

“In addition to executing on our lead development programs, our strategic priorities over the next 12 months will encompass a concerted investor relations outreach strategy and executing on a holistic business development initiative to drive shareholder value. To that end, we are excited by the opportunity to expand on the work we are doing in our partnership with Amgen, and with other leading biotechnology and pharmaceutical companies to apply our novel technology platform to other efficacious injectable products that may benefit from oral delivery,” continued Mr. Gridley. “We currently see three main areas for potential partnerships: (1) companies with leading injectable franchises that are now facing a growing threat from biosimilars, (2) biologics and proteins that may prove to be complementary to our oral delivery platform, as demonstrated by the strategic research collaboration we signed with Amgen in 2018, and (3) opportunities to license EB613 or EB612 globally, or in certain regions of Asia with the goal of rapidly developing and commercializing these products globally.”

Clinical and Corporate Highlights

Phase 2 Study for Oral PTH in osteoporosis: The overall design and registration requirements for the planned pivotal Phase 3 study have been largely defined following the input from the U.S. Food and Drug Administration (FDA) in our pre-IND meeting held in 2018. Coupled with the vast clinical experience with the marketed PTH injection (Forteo® by Lilly®), the Company initiated a dose-ranging, placebo-controlled, Phase 2 study in June 2019. This study will enroll 160 postmenopausal women with osteoporosis or low bone mineral density at four internationally recognized clinical sites in Israel. The primary endpoint of this study is bone formation biomarkers (serum P1NP, a biochemical marker that is correlated with bone formation rate) at 3 months with an additional evaluation at 6 months, of bone mineral density (BMD).

The first patients were recently enrolled, with recruiting and screening efforts underway at all sites. The Company expects enrollment to be completed in the first quarter of 2020, with results from this Phase 2 expected starting in 2020, the first being the interim 3-month biomarker data, followed by the full 3-month and 6-month biomarker data, per the approved study design. These biomarker data, along with the bone mineral density data expected at 6 months, will inform the design of our registrational Phase 3 study. This registrational study is expected to be substantially smaller and less costly than studies used for previously studied PTH products, where the FDA required a fracture endpoint, which historically require thousands of patients over a number of years.

Osteoporosis is a disease in which the density and quality of bone are reduced. As the loss of bone silently progresses, bones become more porous and fragile, greatly increasing the risk of fracture. Worldwide, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds. Worldwide incidence of osteoporosis is estimated to exceed 200 million people[1], with only a small percentage of that population undergoing treatment.

Phase 2b Study for Oral PTH in hypoparathyroidism: Oral PTH for hypoparathyroidism is Entera's second major proprietary pipeline program. Entera completed in 2018 a two-part Phase 2 trial in patients with hypoparathyroidism that was designed to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of its oral PTH drug and injectable PTH (Natpara®).

Results from Part 1 of this study, reported in 2018, demonstrated a positive impact of Oral PTH on three metabolic parameters - serum calcium, phosphate, and 1,25-dihydroxyvitamin D ("active" vitamin D) - in patients with hypoparathyroidism. There was also a decrease in 24-hour urine calcium in the patients treated with Oral PTH.

Part 2 of this PK/PD study evaluated a three times per day (TID) treatment regimen with a high and low dose of Oral PTH, as well as additional Natpara® treatments. Results from this study are expected to be reported in September 2019 at an upcoming scientific conference and are subsequently expected to be submitted for peer review publication in 2020. These data will provide input for the design of the Company's anticipated Phase 3 registration clinical trials.

Personnel Appointments & Anticipated Growth of Operations:

Entera announced a number of personnel appointments, with the appointment of Sean Ellis, a Managing Partner of Centillion Fund, to the Board of Directors in June 2019. In August 2019, Adam Gridley joined the Company as CEO, and Phillip Schwartz, Ph.D., former CEO since the Company's inception in 2010, was appointed as the Company's President of Research & Development and Executive Vice President.

Entera expects to further build out the Company's management teams in the United States and Israel, with several planned executive level hires in the financial and business development functions to support the Company's planned strategic plans. The Company is in the process of establishing a corporate office in the Boston, Massachusetts area.

Investor Relations & Research Coverage:
Frost & Sullivan published an equity research report entitled From Injections to Pills - Entera Bio (ENTX): Initiation of Coverage on July 1, 2019. The Company expects to present at a number of investor conferences over the coming quarters, as well as expanding its investor presence with institutional and retail investors through upcoming non-deal roadshows, and a planned educational event with leading osteoporosis experts, all of which will be webcast and hosted on the Company's investor relations portion of the website.

Financial Results for the Six Months Ended June 30, 2019

Revenues. Revenue for the six months ended June 30, 2019 was $74 thousand from services provided to Amgen.

1 https://www.iofbonehealth.org/facts-statistics

Research and development expenses. Research and development expenses for the six months ended June 30, 2019 were $3.5 million, compared to $4.7 million for the six months ended June 30, 2018, a decrease of $1.2 million, or 25%. The decrease in research and development expenses was primarily attributed to a decrease of $0.8 million in materials, clinical manufacturing and production capabilities and a decrease of $0.5 million in share-based compensation expenses. The decrease was partially offset by an increase of $0.1 million in salaries and related expenses mainly due to hiring of full time employees in the US during the first quarter of 2018.

General and administrative expenses. General and administrative expenses for the six months ended June 30, 2019 were $1.7 million, compared to $0.9 million for the six months ended June 30, 2018, an increase of $0.8 million, or 97%. The increase in general and administrative expenses was primarily attributed to an increase of $0.6 million in share-based compensation expenses due to a reversal of compensation recorded in the previous period as a result of the termination of services of our previous Chairman of the board in the same period in the prior year, an increase of $0.1 million for insurance expenses and $0.1 million of investor relation expenses due to regulation and the requirements of public company.

Financial income. Financial income, net for the six months ended June 30, 2019 was $0.8 million, compared to a financial income, net of $2.9 million for the six months ended June 30, 2018, a decrease of $2.1 million. Financial expenses (income), net for the six months ended June 30, 2019 and for the same period last year, resulted mainly from the change in the fair value of financial liabilities measured at fair value through profit or loss. During the six months ended June 30, 2019 and 2018, we recorded a gain of $0.8 million and $2.9 million, respectively.

Comprehensive loss. Comprehensive loss for the six months ended June 30, 2019 was approximately $4.4 million, compared with approximately $2.6 million in the same period in 2017, an increase of approximately $1.8 million, or 68%.

Basic and Diluted Loss (income) per share. Basic and diluted loss per share for the six months ended June 30, 2019 was $0.38, compared with $0.58 and $0.7 for the six months ended June 30, 2018.

Financial Results for the Three Months Ended on June 30, 2019

Revenues. Revenues for the three months ended June 30, 2019 was $74 thousand from services provided to Amgen.

Research and development, net expenses. Research and development expenses for the three months ended June 30, 2019 were $1.4 million, compared to $1.8 million for the three months ended June 30, 2018, a decrease of $0.4 million, or 20%. The decrease in research and development expenses was primarily attributed to a decrease of approximately $0.3 million in materials, clinical manufacturing and production capabilities and $0.2 million in clinical trials, which was partially offset by an increase of $0.1 million in other research and development expenses primarily for consulting with regard to regulation expenses.

General and administrative expenses (income). General and administrative expenses for the three months ended June 30, 2019 were $0.6 million, compared to general and administrative income of $0.4 million for the three months ended June 30, 2018, an increase in expenses of $1.0 million. The increase in general and administrative expenses was primarily attributed to an increase of $0.9 million in share-based compensation due to a reversal of compensation recorded in the previous period as a result of the termination of services of our previous Chairman of the board. In addition, insurance expenses increased by $0.1 million.

Financial income, net. Financial income, net for the three months ended June 30, 2019 was $0.7 million, compared to a financial income, net of $2.9 million for the three months ended June 30, 2018. Financial income, net for the three months ended June 30, 2019 and for the same period last year, resulted mainly from the change in the fair value of financial liabilities measured at fair value through profit or loss. During the three months ended June 30, 2019 and 2018, we recorded a gain of $0.7 million and $2.9 million, respectively.

Comprehensive loss (income), net. Comprehensive loss for the three months ended June 30, 2019, was approximately $1.4 million, compared with a comprehensive income of approximately $1.6 million in the same period in 2018, an increase in expenses of approximately $2.9 million.

Basic and Diluted Loss (income) per share. Basic and diluted loss per share for the three months ended June 30, 2019 was $0.12 compared with a basic income of $0.35 and diluted loss per share of $0.11, for the three months ended June 30, 2018.

Conference call and webcast, Tuesday, August 20th @ 8:30 am Eastern Time

From the US:	877-407-0784
International:	201-689-8560
From Israel:	1 809 406 247
Conference ID:	13693844
Webcast:	http://public.viavid.com/index.php?id=135865

About Entera Bio Ltd.

Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The Company is initially applying its technology to develop an oral formulation of a human parathyroid hormone analog, Oral PTH (1-34), for treatment of hypoparathyroidism and osteoporosis.

Entera has developed a proprietary platform technology that enables oral delivery of biologicals and large molecule drugs, which are typically delivered via injections and or other non-oral pathways. However, oral drug delivery is the easiest method for self-administering medications, offers patients greater dosing flexibility, and has the highest patient acceptance and compliance rates as compared to all other routes of drug administration. The Company employs this technology for its own pipeline products and may enter into licensing agreements with biopharma companies for application of the technology to their proprietary compounds, such as the Amgen strategic research collaboration. For more information on Entera Bio, visit www.enterabio.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Those risks and uncertainties, include, but are not limited to, the timing and conduct of our clinical trials, the clinical utility of our product candidates, the timing and likelihood of regulatory filings and approvals, our intellectual property position, and our financial position. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note Regarding Forward-Looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(UNAUDITED)

	June 30 2019	December 31 2018
	U.S. dollars in thousands	
CURRENT ASSETS:		
Cash and cash equivalents	7,386	7,506
Short-term bank deposits	-	4,015
Accounts receivable	-	725
Other current assets	486	220
TOTAL CURRENT ASSETS	7,872	12,466
NON-CURRENT ASSETS:		
Property and equipment	231	224
Right to use assets	327	-
Intangible assets	621	651
TOTAL NON-CURRENT ASSETS	1,179	875
TOTAL ASSETS	9,051	13,341
Liabilities and shareholders' equity		
CURRENT LIABILITIES:		
Accounts payable:		
Trade	494	473
Other	939	1,090
Lease liabilities	163	-
Contract liabilities	151	225
TOTAL CURRENT LIABILITIES	1,747	1,788
NON-CURRENT LIABILITIES:		
Warrants to purchase ordinary shares	578	1,372
Lease liabilities	190	-
Severance pay obligations, net	68	65
TOTAL NON-CURRENT LIABILITIES	836	1,437
TOTAL LIABILITIES	2,583	3,225
COMMITMENTS AND CONTINGENCIES		
SHAREHOLDERS' EQUITY:		
Ordinary Shares, NIS 0.0000769 par value:		
Authorized - as of June 30, 2019 and December 31, 2018, 140,010,000 shares; issued and outstanding: as of June 30, 2019, and December 31, 2018 – 11,899,159 shares and 11,459,780 shares, respectively.	*	*
Accumulated other comprehensive income	41	41
Other reserves	13,563	13,019
Additional paid in capital	49,342	49,173
Accumulated deficit	(56,478)	(52,117)
TOTAL SHAREHOLDERS' EQUITY	6,468	10,116
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	9,051	13,341

* Represents an amount less than one thousand.

ENTERA BIO LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

	Six months ended June 30		Three months ended June 30	
	2019	2018	2019	2018
	U.S. dollars in thousands			
REVENUE	(74)	-	(74)	-
COST OF REVENUE	62	-	62	-
RESEARCH AND DEVELOPMENT EXPENSES, NET	3,448	4,658	1,413	1,765
GENERAL AND ADMINISTRATIVE EXPENSES (INCOME)	1,684	854	628	(409)
OPERATING LOSS	5,120	5,512	2,029	1,356
FINANCIAL EXPENSES (INCOME):				
Income from change in fair value of financial liabilities at fair value	(794)	(2,896)	(682)	(2,876)
Other financial expenses (income), net	35	(23)	19	(43)
FINANCIAL INCOME, net	(759)	(2,919)	(663)	(2,919)
NET COMPREHENSIVE LOSS (INCOME) FOR THE PERIOD	4,361	2,593	1,366	(1,563)
	U.S. dollars		U.S. dollars	
LOSS (INCOME) PER ORDINARY SHARE:				
Basic	0.38	0.58	0.12	(0.35)
Diluted	0.38	0.70	0.12	0.11
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:				
Basic	11,601,289	4,490,720	11,742,797	4,490,720
Diluted	11,601,289	4,735,510	11,742,797	9,640,930